Bioelectronics Corp (BIEL)

[3331]

NEW CATALYST!
If 2024 revenues are over $800,000 (report is due in the coming days), it would be a significant improvement over the $700k-ish reported in each of the last two years, which would propel the pps out of the trips. It would also generate some positive publicity in the financial media that would spur future product sales. With the huge USA market available to BIEL last year - after KT previously tried to weaponize their exclusive US rights (2022 and 2023) against us - increased revenue is likely.

BIEL GONNA RUN LIKE 2021!
Everything is falling into place just like 2021. OTC bull market runs are fueled by the Fed cutting interest rates, and the Fed is now forecast to cut five times this year. Falling interest rates indicate a more accommodative money policy which makes investors more interested in the higher risk/higher reward stocks found on the OTC. The last time this happened, BIEL ran more than 1,600% to .0088. The previous BIEL runs coincided with similar OTC bull markets in 2017, 2014 and 2009.

The technical indicators come first - the Golden Cross and the Blue Sky Breakout. Then the fundamentals kick in (Taiwan, VA, Veterinary, New Zealand...). The OTC bull market has begun, as confirmed by Robinhood (favorite for OTC investors) stock outperforming Goldman Sachs (institutional favorite) 150% to 30% over the past few months. BIEL is a Reddit investors dream. Once they become aware of BIEL (via the financial press), the pps will rocket, product sales will soar, and we'll be celebrating like 2021!
https://microcapdaily.com/exciting-week-for-bioelectronics-corp-otcpink-biel/124825/

Expect a 5,000% ROI (pps = .01 from .0002) if BIEL reports a profit in a few days (2024 Annual Report) - or if management hints Q1 (2025) was profitable. This would put BIEL amongst the all-time greatest stocks.
Gemini says "a 5,000% ROI is fantastic but very rare and typically associated with high-risk investments such as penny stocks or early-stage startups".
Copilot says: "achieving a 5,000% return on investment (ROI) is rare and typically involves high-risk stocks, often in emerging industries or during market booms. Some penny stocks, for example, have been highlighted for their potential to deliver such returns".

BIEL's easiest (and most likely) path to success is to generate a $400 - 500k revenue quarter and/or a $1.5 - 2 million revenue year. There are indications this has been - or soon will be - achieved. This would achieve cash flow positive/profitability and increase the pps to copper, which would solve most of BIEL's problems and open up a world of opportunities for our company. The analyses provided below demonstrate the connection between revenues, profitability and the pps using standard analysis methods (it ain't rocket science!). Even if only 10% of the "catalysts" identified below materialize, the pps will still hit copper. This would generate a huge amount of free publicity in the financial and news media (an example of capitalism at it's finest - achieving the American Dream!), which would then lead to an exponential increase in product sales. With BIEL's low operating costs and business model, BIEL could pay off their loans quickly and then use subsequent profits to implement an aggressive stock buyback program, which could rocket the pps to $1+!

Even the BASHERS KNOW HOW CLOSE BIEL IS TO PROFITABILITY, as evidenced by the following posts from the worst of them all:
Post #325074 (12/22/2023)
Positives for BIEL:
1. It's a real company with a real product.
2. The company is not burning $$$ millions every quarter trying to get a product through the FDA wringer. They accomplished that already.
3. The company is very close to profitability every quarter. Just a stone's throw, really.
4. There is no toxic debt. The company is not sinking under death spiral financing.
Down here in the world of sub-penny pink biotech, EACH of these is the exception, not the rule. That makes BIEL.... exceptional!
Yes, BIEL also has its negatives, of which we are all aware. Every pinkie biotech has positives and negatives. But let's give credit where credit is due.
Post #323815 (11/7/23)
I have Staelin penned as a masterful business strategist. He MUST have a plan.
Post #324395 (11/27/23)
Forbes is legit. Now THERE is something worth promoting.
They list pros and cons, and the only real con is that you might need to wear it 12 hours per day... to which I say, bring it on. I have had back pain on and off for many years, caused by moving furniture for Mayflower in my 20's and basically abusing my back my whole life... I wear a back brace most of the time anyway. I'm sure that anyone with chronic back pain agrees with me.
Post #324816 (12/12/2023)
There's nothing so critically wrong with BIEL that it can't be fixed. This company isn't screwing shareholders the way ENDV is screwing shareholders, for example.

BIEL IS THE NEXT AMAZON /APPLE (in terms of ROI)!
When BIEL hits .006, the return on investment for a .0002 buy (for those of us fortunate enough to get them recently) will be about the same as the 10-year ROI (3,000%) for Amazon and Apple (stocks I sold too soon). Microsoft 10-year ROI is ONLY 900%. BIEL can hit .006 in IN THE BLINK OF AN EYE, as $1.5 annual revenue (or a $400k quarter) should do it (due to BIEL's extremely low operating costs and business model). There are many indications that this will be accomplished soon, if it hasn't been already! We know that Taiwan, the VA, South Africa and Bulgaria are in progress, as is RecoveryRx-Veterinary in Europe (with the USA pending). Canada is expanding, New Zealand sales started March 1 and hopefully Australia will soon follow. These new revenue streams should be in addition to the $700k+ earned in each of the past two years.

BIEL is the most undervalued company on the market and SIMPLE TO ANALYZE!
Q3 2021 was BIEL's only profitable quarter ($22,381) with $414,700 revenue (including $100k+ in covid relief funds). PROFITABILITY IS VERY CLOSE! Seems like $1.5 million annual revenue (or a $400k quarter) should do it, due to BIEL's extremely low operating costs and business model. Then the corresponding pps should hit .01 - and increase .01 for each additional $2.5 million annual revenue (P/E = 100). KISS - KEEP IT SIMPLE STUPID! 💋

BIEL is a Venture Capitalist Dream! The opportunity to get in on the "next big thing", but with a company that has been in business for over 20 years (rather than a start-up). BIEL is probably the closest that any of us will get to having a venture capital kind of opportunity.
1) BIEL products have Standard of Care pain management potential for every adult and pet on the planet.
2) BIEL has 5 FDA clearances (with more pending) and the products work extremely well (some say like a miracle).
3) Upside ROI is huge (>10,000%) with minimal downside risk!
4) BIEL should be able to use their China manufacturer to ship directly to their international distributors and Viant for their USA sales to avoid tariffs.

BIEL HITS COPPER WHEN THE FOLLOWING OCCURS!
pps > .001 after management drops some positive hints. The Golden Cross (already achieved) and Blue Sky Breakout will get the technicians/chartists/Reddit crowd attention and the pps out of the trips;
pps > .01 after management drops some positive hints that convinces investors that break even/cash flow positive (annual rev = $1.5 mil) will be achieved, combined with the momentum from a 2021 like OTC run (fueled by the Reddit crowd);
pps > .04 after pr indicates the annual revs from Taiwan (in progress) can be valued at $10 mil+;
pps > .08 after pr indicates the annual revs from the VA (in progress) can be valued at $10 mil+;
pps > .12 after pr indicates the annual revs from RecoveryRx Veterinary (pending) can be valued at $10 mil+;
pps > .16 after pr indicates the annual revs from new contracts (distributors, partners, New Zealand, etc.) can be valued at $10 mil+;
Above pps values are based on P/E = 100
For P/E = 200, pps = .32
For P/E = 300, pps = .48
pps > $1 after loans are paid off and a stock buyback is initiated.

CATALYSTS (Details):
$1.5 million annual revenue (or a $400k quarter) = break even, cash flow positive: PPS = .01.

Taiwan looks like it will be the first catalyst. There are over 80 public hospitals and over 400 private hospitals in Taiwan. They have national health insurance and are rated the world's number one health system.
Assume 100 Taiwan hospitals order 100 Actipatch/RecoveryRx per month @$100 each for BIEL:
$100 x 100 hospitals x 100 x 12 mo = $12,000,000 rev/year.
Using profit = $10 mil and P/E = 100: PPS = .04.
Note: RecoveryRx Veterinary also appears to be in play in Taiwan.

1000 Veterinarian Clinics (USA):
Conservatively assume each office orders 10/mo. @ $100 each for BIEL (Vet sells for $200, a bargain compared to Assisi):
1000 x 100 x 10 x 12 = $12,000,000 rev/year.
Note: RecoveryRx Veterinary also appears to be in play internationally.

There are over 1,000 VA facilities in the U.S. Conservatively assuming 100 VA hospitals order 100 RecoveryRx per month ($100 each for BIEL):
100 x 100 x 100 x 12 = $12,000,000 rev/year.

Sub-total for VA + VET = $20 mil and P/E = 100: PPS = .08!

TOTAL (Taiwan + VA + Veterinary + applying the tax loss carryforward):
pps = .12 (P/E = 100)
pps = .24 (P/E = 200)
pps = .36 (P/E = 300)

Additional revenue could be generated from new FDA clearances, vagus nerve patent, NPA, UK/Australia contract rumor, RecoveryRx Veterinary international sales, New Zealand, etc. Initiating a stock buyback program after all of the loans are paid off would propel the pps much higher (pps = $1).

RECOVERYRX-VETERINARY COULD/SHOULD BE A GOLDMINE!
The Assisi Loop sells over 300/month just on Amazon @ $329, with 1/20 the battery life. Assisi Loop customers are paying the equivalent of over $6,000 when you factor in the additional cost and decreased battery life, but Assisi customers seem happy to pay it based on the 5-star reviews, such as the following from 3-23-2025:
"When applied to the affected area, my dog relaxes a lot. This is the effect we were hoping for. I also tried it on my human back. This product is truly effective."
RECOVERYRX-VETERINARY should be sold as a two/pack - one for the vagus nerve and the other for the area of pain.

Is BIEL the next Microsoft? Those that bought one share of Microsoft at the IPO price of $21 saw their investment increase to $210,000 recently (10,000 X). Someone buying 1 million shares of BIEL @.0002 would see their $200 investment grow to $2,000,000 (pps = $2) with equivalent growth. Is this possible? Absolutely, after BIEL becomes profitable, pays off their loans and then implements an aggressive stock buyback program!